Compare CubeSmart (CUBE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Vertex Pharmaceuticals Incorporated — how do they compare? CubeSmart trades at $37.93 (market cap $8.45B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15.1× CubeSmart's market cap, and CubeSmart pays a 5.65% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CUBE | VRTX | |
|---|---|---|
Market Cap | $8.45B | $127.55B |
Volume | 2,879,532 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $557.96 |
52-Week Low | $35.36 | $407.37 |
Typical Hold Time | 89 Days | 120 Days |
Enterprise Value | $11.97B | $121.68B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.73, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The REIT maintains strong profitability with 29.41% net margins and consistent dividend payments. Recent Q2 2026 earnings showed operational improvement with revenue beats but FFO misses, prompting raised full-year guidance. Institutional activity remains active with several major funds increasing positions in Q2 2026.
CUBE presents a balanced opportunity with 17% upside to consensus target but faces headwinds from moderating earnings growth and high leverage. The stock offers a 5.4% dividend yield while trading at reasonable valuations (P/E 25.5). Key risks include REIT sector pressure and ongoing macroeconomic uncertainty affecting self-storage demand.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
